Walpar Nutritions Ltd
Walpar Nutritions Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Walpar Nutritions Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the half year ended September 30, 2026, is Rs. 4,132.02 Lakhs compared to Rs. 3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase. EBITDA for the quarter: ₹568.21 Lakhs, up 24.18% year-on-year (YoY).
From Walpar Nutritions Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Walpar Nutritions' revenue grow in the September 2026 quarter?
- Revenue from operations for the half year ended September 30, 2026, is Rs. 4,132.02 Lakhs compared to Rs. 3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%.
- The focus is on unaudited standalone and consolidated financial results approved by the Board for the half year ended September 30, 2026.
- The company operates primarily in manufacturing and trading of pharmaceutical, nutritional, herbal, and Ayurvedic commodities.
What happened to Walpar Nutritions' margins in Q2 FY27?
See what Walpar Nutritions Ltd said on profitability & margins — free account, 30 seconds.
What capex is Walpar Nutritions planning?
See what Walpar Nutritions Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Walpar Nutritions raising money or cutting debt?
See what Walpar Nutritions Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Walpar Nutritions' order book?
See what Walpar Nutritions Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Mangalam Drugs (Q2 FY27)
59% growth. Key results statement takeaways from Mangalam Drugs and Organics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Walpar Nutritions Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Walpar Nutritions Ltd Q2 FY27 results?
Revenue from operations for the half year ended September 30, 2026, is Rs. 4,132.02 Lakhs compared to Rs. 3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase. EBITDA for the quarter: ₹568.21 Lakhs, up 24.18% year-on-year (YoY).
What is Walpar Nutritions Ltd share price analysis?
Walpar Nutritions Ltd currently shows a neutral. The stock trades at a P/E of 9.5 with a market cap of ₹23 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Walpar Nutritions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.